



(1) Publication number:

0 414 178 A3

(P)

## **EUROPEAN PATENT APPLICATION**

- 21 Application number: 90115877.4
- 2 Date of filing: 18.08.90

(a) Int. CI.5: C12N 15/12, C12N 15/62, C12N 15/13, C12P 21/02, C12Q 1/70, A61K 37/02, G01N 33/569

- Priority: 23.08.89 US 397782
- Date of publication of application:27.02.91 Bulletin 91/09
- Designated Contracting States:
  AT BE CH DE DK ES FR GB GR IT LI LU NL SE
- Date of deferred publication of the search report: 13.11.91 Bulletin 91/46
- Applicant: THE GENERAL HOSPITAL
   CORPORATION
   55 Fruit Street
   Boston MA 02114(US)
- inventor: Seed, Brian
   Molecular Biology, Wellman 9
   Boston, MA 02114(US)
   inventor: Camerini, David
   1520 Rodney Drive, Apt. 203
   Los Angeles, California 90027(US)
- Representative: Klein, Otto, Dr. et al Hoechst AG Zentrale Patentabteilung Postfach 80 03 20 W-6230 Frankfurt am Main 80(DE)
- (54) Non-human primate CD4 polypeptides and human CD4 molecules capable of being glycosylated.
- The invention relates to substantially pure nonhuman primate CD4, and fragments thereof which bind to HIV or SIV gp120. The invention also relates to gp120 binding molecules related to human CD4 but which may exist in glycosylated form.

The invention also relates to fusion proteins which comprise the CD4 molecules of the invention, or fragments thereof, and an immunoglobulin light or heavy chain, wherein the variable region of the light or heavy chain has been replaced with CD4 or fragment thereof which is capable of binding to gp120. The invention also relates to fusion proteins comprising the CD4 molecules of the invention and a cytotoxic polypeptide.

The invention also relates to an immunoglobulinlike molecules comprising the fusion proteins of the invention together with an immunoglobulin light or heavy chain.

The invention also relates to methods of treating HIV or SIV infection comprising administering the CD4 molecules of the invention, glycoproteins, frag-

ments thereof, fusion proteins or immunoglobulin-like molecules of the invention to an animal.

The invention also relates to assays for HIV or SIV comprising contacting a sample suspected of containing HIV or SIV gp120 with the CD4 molecules of the invention, fragments thereof, glycoproteins, immunoglobulin-like molecules, or fusion proteins of the invention, and detecting whether a complex is formed.

The invention also relates to nucleic acid molecules which specify the proteins, glycoproteins and fusion proteins of the invention as well as vectors and transformed hosts.

## EUROPEAN SEARCH REPORT

EP 90 11 5877

DOCUMENTS CONSIDERED TO BE RELEVANT				<u> </u>
ategory		with indication, where appropriate, elevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. CI.5)
Υ	CFLL vol 42 August 198	5, pages 93-104; P.J. MADDON et	1-30	C 12 N 15/12
•		electide sequence of a cDNA	1 1-30	1
			i	. C 12 N 15/62
·		e protein T4: A new member of	ł	C 12 N 15/13
	the immunoglobulin gene			C 12 P 21/02
	* Summary; Introduction; I	Results; especially figure 6 *		C 12 Q 1/70
	-			A 61 K 37/02
Υ	EP-A-0 314 317 (GENEN	ITECH, USA)(03-05-1989)	1-30	G 01 N 33/569
	* Page 3, lines 11-38; page	es 4,5; claims *		
Υ		RUSTEES OF COLUMBIA UNI-	1-30	
	VERSITY IN THE CITY OF	F NEW YORK, US)(25-02-1988)		
	* Summary; pages 16-23;			1
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		1	
A I	NATURE, vol. 331, no. 615	51, 7th January 1988, pages	1-30	İ
		: "A soluble CD4 protein selec-	1 . 22	1
		on and syncytium formation"	ì	
		on and syncytium formation."	1	'
	* The whole document *			
,	MATHER COCC			
		51, 7th January 1988, pages	1-30	
		t al.: "Soluble CD4 molecules		Ĺ
	neutralize human immunoc	leficiency virus type 1"	l	TECHNICAL FIELDS
	* The whole document *		ľ	SEARCHED (Int. CI.5)
- 1		<b></b>		0.07.14
A	NATURE, vol. 331, no. 615	1, 7th January 1988, pages	1-30	C 07 K
ji	82-84; K.C. DEEN et al.: "A	A soluble form of CD4 (T4) protein	1	C 12 N
	inhibits AIDS virus infection		ĺ	
	* The whole document *	•		
			1	
a li	NATURE vol 331 no 615	1, 7th January 1988, pages	1-30	
7   t		"HIV infection is blocked in vitro	1-30	
			]	
	by recombinant soluble CD	/ <b>4</b> "	i	
1	The whole document *	*.		
	~	<b>~ ~ ~</b>		
- }				
	•			
	•			
	The present search report has	peen drawn up for all claims		·
	Place of search Date of completion of search			Examiner
		02 September 91		NAUCHE S.A.
	CATEGORY OF CITED DOCL		r patent docum	ent, but published on, or after
	rticularly relevant if taken alone	the fil	ing date	•
	rticularly relevant If combined wit	h another D: docum	ent cited in the	
document of the same catagory  A: technological background			nent cited for o	Iner reasons
	n-written disclosure	&: memb	er of the same	patent family, corresponding
	ermediate document			